Immunotherapy drugs with standard treatment for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy and radiation for people with newly diagnosed, stage IVA nasopharyngeal cancer. The goal is to see if adding these drugs improves the chances of controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have newly diagnosed nasopharyngeal cancer that is stage IVA (has spread to lymph nodes but not to other organs).
- You have not had chemotherapy or radiation for this cancer before.
- You are in generally good health (able to care for yourself and up and about more than 50% of waking hours).
- You have not had major surgery in the past 4 weeks.
- You are not pregnant or breastfeeding, and if you could have children, you agree to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy before standard radiation for advanced nasopharyngeal cancer. It aims to shrink tumors and improve outcomes.
This trial tests whether adding an immunotherapy drug (which helps your immune system fight cancer) to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer (a type of cancer in the upper throat). If you qualify, you would receive this combination treatment as your first therapy for this stage of disease.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This study tests two immunotherapy medicines (iparomlimab and tuvonralimab) combined with radiation and standard chemotherapy for advanced head and neck cancer that cannot be removed with surgery. The goal is to see if adding these medicines helps shrink tumors and improve outcomes.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Hear when a new Locally Advanced Nasopharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.